Problem
Many preclinical programmes stall because the chosen models and CROs don’t reflect the clinical biology they aim to treat. Project teams often pick a vendor for price or convenience and discover later that the animal models, endpoints, or dosing strategies aren’t aligned with human metabolic disease pathology. A careful search for a metabolic disease CRO that understands study design, reproducibility, and regulatory context prevents wasted months and budget.
Why this matters now
Drug candidates for conditions like nonalcoholic steatohepatitis require models that reproduce inflammation, fibrosis progression, and metabolic stress. I’ve seen study plans reset after major conferences such as the AASLD annual meeting in Boston when clinical-pathology correlations were clarified; that sort of field-level learning shapes realistic go/no-go decisions. Work with a NASH specialist, for example a NASH CRO with validated diet-induced and toxin-accelerated models, and you’ll reduce the risk of chasing non-translatable signals.
Common pitfalls teams repeat
Designing endpoints that look good on paper but miss clinical relevance. Using juvenile animals when the human disease is adult onset. Relying only on single histology readouts rather than combining imaging, serum biomarkers and histopathology. Overlooking randomisation and blinding until late. Expecting identical PK/PD between species without bridging studies. Each of these produces false positives or uncertain reads that delay decisions.
How to evaluate vendors
Ask for transparent assay SOPs, historical control ranges, blinded slide sets, and raw data access. Confirm reproducibility by requesting example datasets from comparable programmes. Check for integrated pharmacology: can they merge histology with imaging and biomarker panels? Confirm the team’s hands-on experience rather than titles; ask for lead scientist CVs and published models. Pricing clarity matters, but capacity and technical match matter earlier.
Practical checklist and mistakes to avoid
Create a checklist: clear primary endpoint; pre-specified secondary endpoints; power calculations; SOPs for necropsy and histology; predefined PK sampling windows; and a contingency for non-responders. Avoid the trap of adding exploratory endpoints mid-study. Don’t accept vague timelines for pathology reads. Build governance: a short steering group with the sponsor and the study lead to resolve issues quickly.
Closing synthesis
Problem-driven choices—selecting models, endpoints and partners that reflect human disease—drive whether a programme progresses or stalls. Practical vetting and firm study governance reduce uncertainty and speed go/no-go calls; that is the value a well-matched partner brings, as seen when teams adopt consistent, clinically relevant endpoints and robust data sharing with KCI Biotech.
